Semaglutide vs Resmetirom in MASH

This was an exploratory indirect comparison, not a randomized head-to-head trial of semaglutide and resmetirom. The authors compared published placebo-adjusted results from the separate ESSENCE and MAESTRO-NASH trials. Their analysis suggested an advantage for semaglutide over resmetirom 80 mg on MASH resolution, while fibrosis improvement looked broadly comparable. Differences between the original trials could still explain part of that pattern, so the paper cannot establish that one drug caused better outcomes than the other.^[1]

PubMed classifies the article as a Letter, and the full text calls it a Research Letter. It did not enroll a new cohort. The calculation used aggregate, published estimates rather than individual participant data, and the authors state that adjustment for baseline differences between trials was not possible.^[2]

How the indirect comparison was built

The researchers extracted each medicine's absolute treatment difference versus placebo from a separate phase 3 trial. MAESTRO-NASH supplied estimates for resmetirom at 80 mg and 100 mg per day. ESSENCE supplied the estimate for semaglutide 2.4 mg per week. The analysis then subtracted the semaglutide treatment effect from the resmetirom treatment effect.^[1]

Two histological endpoints were examined. The first was MASH resolution without worsening of fibrosis. The second was improvement in liver fibrosis without worsening of MASH. Both original programmes enrolled people with MASH and fibrosis stages F2 or F3, but that shared eligibility does not make their populations identical.^[3]

The authors also repeated the calculation in published subgroups defined by sex, age, body mass index, type 2 diabetes and baseline fibrosis stage. These were comparisons of subgroup estimates from different trials, not randomized subgroup assignments within one trial. The method assumed that the trials were sufficiently comparable for the subtraction to be informative.^[1]

What the MASH resolution result showed

For MASH resolution without worsening fibrosis, semaglutide showed a statistically greater indirect benefit than resmetirom 80 mg in the overall analysis. The reported risk difference was -0.123, with a 95% confidence interval from -0.215 to -0.031. The sign reflects the authors' resmetirom-minus-semaglutide calculation, so the negative result favoured semaglutide.^[3]

The same analysis favoured semaglutide 2.4 mg over resmetirom 80 mg in some published subgroups, including women and people younger than 65. It also found a difference in those with BMI at least 35, participants without type 2 diabetes and those with F3 fibrosis. The remaining subgroup comparisons were not significant.^[1]

Against resmetirom 100 mg, semaglutide only showed a non-significant trend on MASH resolution in the overall populations. The risk difference was -0.080, with a 95% confidence interval from -0.173 to 0.013. Because that interval includes no difference, the analysis did not establish superiority over the 100 mg dose.^[3]

Fibrosis improvement looked different

For fibrosis improvement without worsening MASH, the authors found no significant difference between semaglutide and either resmetirom dose in the overall populations. Most subgroup comparisons were also not significant. One exception favoured semaglutide among participants without type 2 diabetes in the 80 mg comparison.^[1]

That split between endpoints matters. MASH resolution and fibrosis improvement describe related but distinct histological changes. A result favouring semaglutide on the first endpoint should not be rewritten as proof of stronger anti-fibrotic efficacy. The paper itself describes fibrosis effects as broadly comparable within the limits of the indirect method.

Our semaglutide research overview keeps these liver findings separate from evidence in diabetes and obesity. An indirect MASH comparison cannot answer how an individual will respond, and it does not replace the underlying trial reports.

Why the comparison cannot rank the drugs

The authors list the central limitation plainly: they used aggregate published data, not individual participant records. They could not adjust for baseline differences in demographics, metabolic characteristics or disease severity. Placebo response also differed between the source trials, which can alter a placebo-adjusted comparison.^[3]

Methods were not perfectly aligned either. The paper notes differences in how missing end-of-trial biopsy data were handled. Pathology reading and endpoint adjudication may also have introduced heterogeneity. An indirect comparison depends on transitivity, the assumption that trial differences do not distort the treatment contrast. That assumption cannot be confirmed by subtracting published estimates.^[1]

The subgroup findings need even more restraint. They came from published subgroup estimates that were not prospectively harmonized across the two programmes. A pattern in women, people without diabetes or those with F3 fibrosis can generate a hypothesis. It cannot support choosing one medicine for that subgroup without a direct randomized comparison.

What we don't yet know

No randomized head-to-head trial has shown whether semaglutide or resmetirom produces better liver outcomes in the same MASH population. This analysis also does not test sequential treatment or combination therapy. The authors discuss those strategies as hypotheses and say comparative and combination trials are required.^[3]

Long-term clinical outcomes remain outside this calculation. Histology can inform regulatory and research decisions, but this letter does not estimate differences in liver decompensation, transplantation or mortality. Readers seeking established adverse-effect context can consult the semaglutide safety section. It should not be used to infer resmetirom safety or a combination's safety.

Authorization also stays separate from comparative efficacy. Our semaglutide regulation overview tracks jurisdiction-specific status. The research doses described here are features of the source trials and are not treatment instructions.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.